🇺🇸 FDA
Patent

US 9040543

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/505A61K31/506

Quick answer

US patent 9040543 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 26 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/505, A61K31/506, A61K31/5377, A61K31/5383